OVERVIEW

AJMC Payer Forum: Reducing Influenza Duration, Related Complications and Healthcare Costs with Novel Antivirals is organized by Pharmacy Times Continuing Education (PTCE).

Date:-
Start Date:- May 17, 2019
End Date:- May 30, 2020.

Target Audience:
Managed care professionals and retail pharmacists

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)

Course Description:
Despite the availability of a vaccine and treatment options, influenza continues to pose a significant economic and healthcare burden. Data have shown that the use of antiviral treatment in the early stages of influenza can decrease the duration of fever and illness symptoms and can even lessen the risk of complications associated with the illness especially in high-risk individuals. New drug approvals create opportunities to effectively and safely treat influenza. During this AJMC® Payer Forum, expert faculty will facilitate discussion on the identification of patients who may have influenza or who are at a high risk of complications as well as the guideline recommendations to effectively manage these patients. Managed care organizations can employ prevention and treatment strategies to diminish associated complications, hospitalizations, and mortality rates associated with this illness.

Educational Objectives:
Upon completion of this educational activity, participants will be able to:
• Identify patients at high risk for complications from the influenza virus
• Explore the safety and efficacy of available and emerging antivirals for the treatment of influenza virus
• Explain the role of new influenza virus treatment options in a population health model
• Illustrate the impact of direct and indirect costs to influenza virus

Additional details will be posted as soon as information is available.